Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer by Brugger Wolfram, Triller Nadja, Blasinska-Morawiec Maria, Curescu Stefan, Sakalauskas Raimundas, Manikhas Georgy Moiseevich, Mazieres Julien, Whittom Renaud, Ward Carol, Mayne Karen, Trunzer Kerstin, Cappuzzo Federico in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PubMed

Abstract

The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended progression-free survival (PFS) and overall survival in patients with advanced non-small-cell lung cancer (NSCLC) who had nonprogressive disease following first-line platinum-doublet chemotherapy. This study included prospective analysis of the prognostic and predictive value of several biomarkers.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

Sign in to see variant annotations.